A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Clinical trial NCT02600897 · COMPLETED

Trial details

NCT number: NCT02600897
Sponsor: Hoffmann-La Roche
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Start date: 2016-03-24
Primary completion: 2021-12-15
Enrollment: 114

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.